## **Supplementary Information**

Α

Patient Number	Age	Sex	WHO Classification	Pathological Diagnosis
1	41	Male	II	Oligodendrocyte
2	51	Female	IV	Glioblastoma
3	43	Male	II	Astroglioma
4	38	Male	IV	Glioblastoma
5	45	Female	II	Astroglioma
6	75	Female	III	Anaplastic astrocytoma
7	14	Female	IV	Glioblastoma
8	39	Male	Ι	Pilocytic astrocytoma
9	44	Male	IV	Glioblastoma
10	52	Female	II	Oligodendrocyte
11	45	Female	IV	Glioblastoma
12	55	Male	Ι	Pilocytic astrocytoma
13	58	Female	IV	Glioblastoma
14	53	Male	II	Astroglioma
15	52	Male	III	Anaplastic astrocytoma
NG1 N	(5 <sup>2</sup>		В	
st sientst sien			В	MTS assay
se sientri sien	ුරුට -GCF -p-ST		В	MTS assay
f ste <sup>nten</sup> sten	-GCI	TAT3		<b>MTS assay</b> iC
k sientsi sien	-GCF -p-ST	TAT3 T3	4 <b>]</b> → s s	iC iGCN5-1
e sentra sen	-GCM -p-ST	ГАТЗ ТЗ КТ	4 → s 	iC
E stewfor stew	-GCF -p-S <sup>-</sup> -STA -p-A	ГАТЗ ТЗ КТ Г	4 → s 	iC iGCN5-1
E siewich siew	-GCF -p-ST -STA -p-A -AKT	ГАТЗ ТЗ КТ Г	4 → s 4 → s 3 → s 2- 0	iC iGCN5-1
E siewich siew	-GCI -p-ST -STA -р-А -AKT -РСМ	ГАТЗ ТЗ КТ Г IA IP9	4 → s 3 → s	iC iGCN5-1
E stewfrit stew	-GCI -p-ST -STA -p-A -AKT -PCN	ГАТЗ ТЗ КТ Г IA IP9	4 → s 4 → s 3 → s 2- 0	iC iGCN5-1

Table S1. Characteristics of Glioma patients

**Figure S1.** (A) GCN5 knockdown decreased the expression of p-STAT3, p-AKT, PCNA, MMP9 and increased the expression of p21 in CHG5 cell; and (B) MTS assay indicated that GCN5 knockdown suppressed cell growth rate in CHG5 cell (\* p < 0.05).